Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, phase II clinical trial that will enroll metastatic
colorectal cancer patients with Cetuximab-Related Skin Toxicity, who will receive crisaborole
ointment twice daily.